INT332622

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.11
First Reported 2010
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 1
Total Number 2
Disease Relevance 0.94
Pain Relevance 0.21

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

signal transduction (Glp1r) plasma membrane (Glp1r) signal transducer activity (Glp1r)
Glp1r (Mus musculus)
Pain Link Frequency Relevance Heat
agonist 8 82.40 Quite High
tolerance 14 55.36 Quite High
Paracetamol 2 53.76 Quite High
Inflammation 10 5.00 Very Low Very Low Very Low
pruritus 4 5.00 Very Low Very Low Very Low
headache 4 5.00 Very Low Very Low Very Low
cytokine 2 5.00 Very Low Very Low Very Low
fibrosis 2 5.00 Very Low Very Low Very Low
Neuropeptide 2 5.00 Very Low Very Low Very Low
abdominal pain 2 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Diabetes Mellitus 190 96.00 Very High Very High Very High
Overweight 4 87.76 High High
Body Weight 2 67.88 Quite High
Hyperglycemia 22 40.52 Quite Low
Hypoglycemia 58 27.08 Quite Low
Gastric Motility Disorder 2 17.84 Low Low
Insulin Resistance 32 5.00 Very Low Very Low Very Low
Obesity 20 5.00 Very Low Very Low Very Low
Atherosclerosis 20 5.00 Very Low Very Low Very Low
Heart Rate Under Development 18 5.00 Very Low Very Low Very Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
To overcome the rapid degradation of GLP-1 by DPP-4,127 two approaches have been developed, ie, alteration of the peptide structure of GLP-1 to prevent its degradation by DPP-4, but allow GLP-1 receptor activation, and development of DPP-4 inhibitors, which block the degradation of GLP-1 by DPP-4, thus increasing the reduced concentrations of GLP-1 back to normal physiologic levels in T2DM.
Negative_regulation (block) of Protein_catabolism (degradation) of GLP-1 associated with diabetes mellitus
1) Confidence 0.11 Published 2010 Journal Vascular Health and Risk Management Section Body Doc Link PMC2941781 Disease Relevance 0.47 Pain Relevance 0.15
To overcome the rapid degradation of GLP-1 by DPP-4,127 two approaches have been developed, ie, alteration of the peptide structure of GLP-1 to prevent its degradation by DPP-4, but allow GLP-1 receptor activation, and development of DPP-4 inhibitors, which block the degradation of GLP-1 by DPP-4, thus increasing the reduced concentrations of GLP-1 back to normal physiologic levels in T2DM.
Negative_regulation (prevent) of Protein_catabolism (degradation) of GLP-1 associated with diabetes mellitus
2) Confidence 0.08 Published 2010 Journal Vascular Health and Risk Management Section Body Doc Link PMC2941781 Disease Relevance 0.47 Pain Relevance 0.06

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox